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Eleven loci with new reproducible genetic
associations with allergic disease riskManuel A. R. Ferreira, PhD,a Judith M. Vonk, PhD,b Hansj€org Baurecht, PhD,c Ingo Marenholz, PhD,d,e Chao Tian, PhD,f
Joshua D. Hoffman, PhD,g Quinta Helmer, PhD,h Annika Tillander, PhD,i Vilhelmina Ullemar, PhD,i
Yi Lu, PhD,i Franz R€uschendorf, PhD,d the 23andMe Research Team,f the collaborators of the SHARE study,*
David A. Hinds, PhD,f Norbert H€ubner, MD,d Stephan Weidinger, MD,c Patrik K. E. Magnusson, PhD,i
Eric Jorgenson, PhD,j Young-Ae Lee, MD,d,e Dorret I. Boomsma, PhD,h Robert Karlsson, PhD,i Catarina Almqvist, MD,i,k
Gerard H. Koppelman, MD,l and Lavinia Paternoster, PhDm Brisbane, Australia; Groningen and Amsterdam, The
Netherlands; Kiel and Berlin, Germany; Mountain View, San Francisco, and Oakland, Calif; Stockholm, Sweden; and Bristol, United
KingdomBackground: A recent genome-wide association study (GWAS)
identified 99 loci that contain genetic risk variants shared
between asthma, hay fever, and eczema. Many more risk loci
shared between these common allergic diseases remain to be
discovered, which could point to new therapeutic opportunities.
Objective: We sought to identify novel risk loci shared between
asthma, hay fever, and eczema by applying a gene-based test of
association to results from a published GWAS that included
data from 360,838 subjects.
Methods: We used approximate conditional analysis to adjust the
results from the published GWAS for the effects of the top risk
variants identified in that study. We then analyzed the adjusted
GWAS results with the EUGENE gene-based approach, which
combines evidence for association with disease risk across
regulatory variants identified in different tissues. Novel gene-
based associations were followed up in an independent sample of
233,898 subjects from the UK Biobank study.
Results: Of the 19,432 genes tested, 30 had a significant gene-
based association at a Bonferroni-correctedP value of 2.53 1026.
Of these, 20 were also significantly associated (P <.05/305 .0016)
with disease risk in the replication sample, including 19 that were
located in 11 loci not reported to contain allergy risk variants in
previous GWASs. Among these were 9 genes with a known
function that is directly relevant to allergic disease: FOSL2,From aGenetics and Computational Biology, QIMR Berghofer Medical Research Insti-
tute, Brisbane; bEpidemiology, University of Groningen, University Medical Center
Groningen, Groningen Research Institute for Asthma and COPD; cthe Department
of Dermatology, Allergology and Venereology, University Hospital Schleswig-Hol-
stein, Campus Kiel; dMax Delbr€uck Center (MDC) for Molecular Medicine, Berlin;
ethe Clinic for Pediatric Allergy, Experimental and Clinical Research Center of Charite
Universit€atsmedizin Berlin and Max Delbr€uck Center, Berlin; f23andMe, Inc,
Mountain View; gthe Department of Epidemiology and Biostatistics, University of
California San Francisco; hthe Department Biological Psychology, Netherlands
Twin Register, Vrije University, Amsterdam; ithe Department of Medical
Epidemiology and Biostatistics and the Swedish Twin Registry, Karolinska Institutet,
Stockholm; jthe Division of Research, Kaiser Permanente Northern California,
Oakland; kthe Pediatric Allergy and Pulmonology Unit at Astrid Lindgren Children’s
Hospital, Karolinska University Hospital, Stockholm; lthe University of Groningen,
University Medical Center Groningen, Beatrix Children’s Hospital, Pediatric
Pulmonology and Pediatric Allergology, and University of Groningen, University
Medical Center Groningen, Groningen Research Institute for Asthma and COPD,
Groningen; and mMRC Integrative Epidemiology Unit, School of Social and
Community Medicine, University of Bristol.
*Collaborators of the SHARE study are listed in this article’s Online Repository at www.
jacionline.org.
This research has been conducted using the UK Biobank Resource under Application no.
10074. M.A.R.F. was supported by a Senior Research Fellowship (APP1124501) from
the National Health andMedical Research Council (NHMRC) of Australia. J.D.H. was
supported by National Institutes of Health (NIH) postdoctoral training grantVPRBP, IPCEF1, PRR5L, NCF4, APOBR, IL27, ATXN2L, and
LAT. For 4 genes (eg,ATXN2L), a genetically determined decrease
in gene expressionwas associatedwith decreased allergy risk, and
therefore drugs that inhibit gene expression or function are
predicted to ameliorate disease symptoms. The opposite
directional effect was observed for 14 genes, including IL27, a
cytokine known to suppress TH2 responses.
Conclusion: Using a gene-based approach, we identified 11 risk
loci for allergic disease that were not reported in previous
GWASs. Functional studies that investigate the contribution of
the 19 associated genes to the pathophysiology of allergic disease
and assess their therapeutic potential are warranted. (J Allergy
Clin Immunol 2019;143:691-9.)
Key words: Rhinitis, atopic dermatitis, atopy, genome-wide associ-
ation study, transcriptome
The strong genetic correlations between asthma, hay fever, and
eczema estimated from twin studies1-5 in combination with the
highly polygenic architecture of these diseases predict that
many hundreds, if not thousands, of genetic risk factors are shared
among these 3 common allergic diseases. Motivated by this pre-
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between asthma, hay fever, and eczema.6 In that GWAS cases
(n 5 180,129) were defined as subjects who reported having 1
or more allergic diseases, whereas control subjects
(n 5 180,709) were subjects who reported never having any of
these diseases. We identified 136 single nucleotide polymor-
phisms (SNPs) located in 99 loci (ie, genomic regions located
>1 Mb apart) that were independently associated with disease
risk at a genome-wide significance threshold P value of less
than 3 3 1028, a threshold that corrects for the number of
SNPs tested.7 In our study we often observed that multiple inde-
pendent genetic variants within one locus contributed to disease
risk; this was the case for 18 of the 99 risk loci identified.
Larger GWASs of this multidisease phenotype are underway
and expected to identify more risk variants shared between
asthma, hay fever, and eczema. Here we report results from
another approach that increases power to identify novel risk loci:
gene-based instead of SNP-based association analysis. Different
gene-based tests have been developed, including VEGAS,8
MAGMA,9 and fastBAT.10 For each gene in the genome, these
methods combine in a single test the evidence for association
with a disease across multiple SNPs, which are typically selected
because they are located in or near that gene (eg, within 100 kb).
These methods improve power over the alternative approach of
testing each SNP at a time (as is done in a GWAS) when multiple
SNPs near a gene are associated independently with disease risk.
However, not all SNPs near a gene are directly relevant to its
function. For example, only some SNPs influence variation in
gene expression levels; these are commonly referred to as
expression quantitative trait loci (eQTLs). On the other hand,
eQTLs have a greater probability of being associated with
common diseases and traits.11
Based on these observations, an additional suite of gene-based
methods has been developed recently that only include in the
association test functional SNPs, such as eQTLs. These include
PrediXcan,12 EUGENE,13 and S-PrediXcan.14 We developed
EUGENE because it was not possible with other methods to
combine in the same association test information from eQTLs
identified in different tissues. This feature is important because
multiple tissue types play a role in allergic disease
pathophysiology and tissue-specific eQTLs are common.15
Furthermore, EUGENE also considers regulatory variants with
different mechanisms of action, such as variants that affect
splicing but not overall transcription levels. This increased
resolution is expected to increase our ability to identify genes
that are causally related to common diseases.16
The aims of the present studywere to (1) identify novel risk loci
shared between asthma, hay fever, and eczema by applying
EUGENE to results from our previous GWAS6 and (2) follow upthe top gene-based associations in an independent replication
sample ascertained from the UK Biobank study.17METHODS
Adjusting GWAS results for the effects of genome-
wide significant SNPs
The starting point for this study was a GWAS of allergic disease reported
recently by Ferreira et al,6 which included 360,838 subjects from 13 studies:
UK Biobank, 23andMe, GERA, CATSS, NTR, LifeLines, TWINGENE, AL-
SPAC, SALTY, GENEVA, AAGC, GENUFAD-SHIP-1, and GENUFAD-
SHIP-2 (demographics are provided in Table E1 in this article’s Online Repos-
itory at www.jacionline.org). In that study single-SNP results were corrected
for an inflation factor that reflected technical biases and/or population stratifi-
cation (specifically, a linkage disequilibrium [LD] Score regression intercept18
of 1.04). After that correction, there were 136 variants associated indepen-
dently with allergic disease in the study by Ferreira et al.6
Because our aim was to identify new allergy risk loci, we first applied
approximate conditional analyses, as implemented in the GCTA tool,19 to the
summary statistics of Ferreira et al6 to adjust the single-SNP results for the ef-
fects of the 136 risk variants (a detailed justification for performing condi-
tional analysis before the gene-based analysis is provided in the Methods
section in this article’s Online Repository at www.jacionline.org). In the con-
ditional analysis, LD between SNPs was estimated based on genotype data
from 5000 subjects from the UK Biobank study.17Gene-based analysis of the adjusted GWAS results
To identify novel risk loci shared between asthma, hay fever, and eczema,
we analyzed the adjusted GWAS results with EUGENE,13 a gene-based
approach that is applicable to summary statistics (ie, it does not require
individual-level genetic data for subjects included in the GWAS) and com-
bines evidence for association with disease risk across eQTLs identified in
different tissues. The latter feature is important because multiple tissue types
play a role in allergic disease pathophysiology and tissue-specific eQTLs are
common.15
We identified eQTLs based on information from 39 published eQTL studies
conducted in 19 tissues or cell types relevant to allergic disease (see Table E2
in this article’s Online Repository at www.jacionline.org). For each eQTL
study, we (1) downloaded the original publication tables containing results
for the eQTLs reported; (2) extracted the SNP identifier, gene name, associa-
tion P value, and directional effect (if available; b/z score and effect allele) for
all reported eQTLs; and (3) excluded eQTLs located more than 1 Mb of the
respective gene (ie, trans-eQTLs) and/or with an association P value of greater
than 2.33 1029, a conservative threshold that corrects for 21,742 genes in the
genome, each tested for association with 1,000 SNPs (as suggested by
others).20-22 We did not include trans-eQTLs in the analysis because often
these are thought to involve indirect effects,23 such aswhere an SNP influences
the expression of a gene in cis, which in turn affects the expression of many
other genes in trans.
Having identified a list of cis-eQTLs for a given gene from published
studies, we then reduced that list to a set of eQTLs in low LD with each other
(specifically, with an r2 < 0.1) using the –clump procedure in PLINK, version
1.90.24 For a given gene, we refer to these as ‘‘independent eQTLs,’’ although
we recognize that some pairs of eQTLs will not be in linkage equilibrium. LD
was estimated based on genetic data from individuals of European descent
from the 1000 Genomes Project (n5 294, release 20130502_v5a). Clumping
was not performed separately for each tissue or study but rather applied to the
overall list of eQTLs obtained after considering information from all
tissues/studies. If an eQTL was identified in multiple tissues/studies, the
clumping procedure was performed with the smallest P value reported for
that eQTL across all tissues/studies. A file (ASTHMA.20170517.eqtl.
proxies.list) containing the independent eQTLs identified per gene is available
at https://genepi.qimr.edu.au/staff/manuelF/eugene/main.html.
For each gene, EUGENE extracts single-SNP association results for each
independent eQTL (or, if not available, for a proxy with an r2 value >0.8) from
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eQTLs, and estimates the significance of the resulting sum test statistic by us-
ing the Satterthwaite approximation, which accounts for the LD between
eQTLs. This approximation was originally implemented by Bakshi et al10
in the GCTA-fastBAT module and is now also available in EUGENE. LD
between eQTLs was estimated based on data from 294 European
subjects from the 1000 Genomes Project (release 20130502_v5a). The
significance threshold required to achieve experiment-wide significance was
set at a P value of less than .05/N genes tested.
Replication of significant gene-based associations
in an independent sample
To confirm novel gene-based associations, we analyzed an independent
sample of unrelated subjects of European descent from the UK Biobank
study.17 The approach used to select subjects for analysis was very
similar to that described in detail previously.6 Briefly, we (1) downloaded
array (805,426 variants) and imputed (92,693,895 variants) genetic data
for the entire UK Biobank study, comprising 488,377 subjects, in June
2017; (2) pruned the array data down to a set of 29,446 independent
SNPs that had comparable (P > .005) allele frequencies between
European subjects of the 1000 Genomes Project (CEU, FIN, GBR, and
TSI groups) and the UK Biobank subjects of European descent included
in the GWAS by Ferreira et al6; (3) merged the pruned data set with data
from 1,092 subjects of known ancestry from the 1000 Genomes Project
(release 20130502_v5a); (4) performed multidimensional scaling analysis
of identity-by-state allele sharing separately for each of 32 groups of
approximately 16,000 subjects (to be computationally feasible), including
those from the 1000 Genomes Project; (5) identified and removed
subjects who did not cluster closely (within 5 SDs of multidimensional
scaling components 1 and 2) to subjects of European ancestry from the
1000 Genomes Project, resulting in 461,885 subjects; and (6) identified
and removed any subjects included in or related to (ie, with a kinship
coefficient that indicates third-degree relatedness or closer based on file
ukb1007_rel_s488374.dat) the 138,354 subjects of the UK Biobank
study included in Ferreira et al,6 as well as subjects (A) with
genetically inferred sex different from self-reported sex, (B) who were
outliers for SNP missingness or genome-wide heterozygosity levels,
and/or (C) with more than 10 third-degree relatives, resulting in
244,395 subjects.
For each subject, allergic disease status was defined as previously described
for the UK Biobank study in detail.6 To classify asthma status, we combined
information from 3 sources: (1) touchscreen questionnaires (data field 6152);
(2) noncancer illness code, self-reported during verbal interview (data field
20002); and (3) main (data field 41202) and secondary (data field 41204)
International Classification of Diseases, Tenth Revision (ICD-10), diagnoses.
Specifically, inclusion criteria for cases were as follows: (1) a report of
‘‘asthma’’ in field 6152 and a code for asthma (1111) in field 20002 or
(2) an ICD-10 code for asthma in fields 41202 or 41204. Exclusion criteria
for cases were as follows: (1) a report of chronic obstructive pulmonary dis-
ease in fields 6152 or 20002 or (2) other self-reported respiratory diseases
in field 20002. Inclusion criteria for control subjects were no report of asthma
in fields 6152, 20002, 41202, and 41204. Exclusion criteria for control
subjects were the same as for cases (no chronic obstructive pulmonary disease
or other self-reported respiratory diseases).
To classify hay fever status, we used the same 3 sources of information.
Specifically, inclusion criteria for cases were as follows: (1) a report of ‘‘hay
fever, allergic rhinitis or eczema’’ in field 6152 and a code for hay fever (1387)
in field 20002 or (2) an ICD-10 code for hay fever in fields 41202 or 41204.
Inclusion criteria for control subjects were no report of hay fever in fields
6152, 20002, 41202, and 41204.
The eczema phenotype was created very similarly to the hay fever
phenotype. Inclusion criteria for cases were as follows: (1) a report of ‘‘hay
fever, allergic rhinitis or eczema’’ in field 6152 and a code for eczema (1452)
in field 20002 or (2) an ICD-10 code for eczema in fields 41202 or 41204.
Inclusion criteria for control subjects were no report of eczema in fields 6152,
20002, 41202, and 41204.To create the overall allergic disease phenotype used for analysis, cases
were subjects classified as having at least 1 condition (asthma and/or hay fever
and/or eczema), as described above. Control subjects were subjects classified
as not having any of the 3 conditions. By using this approach, the 244,395
subjects selected for analysis (see above) included 71,807 allergic disease
cases, 162,091 allergic disease control subjects, and 10,497 subjects with a
missing phenotype.
SNPTESTwas then used to test the association between disease status and
imputed genotype data for eQTLs of genes selected for replication; age, sex,
and SNP chip were included as covariates. We analyzed only SNPs imputed
based on the Haplotype Reference Consortium panel, given that variants
imputed from the UK10K plus 1000 Genomes panel were not mapped
correctly. Association results from 1.2 million HapMap3 SNPs were used to
estimate the degree of inflation in test statistics arising because of
unaccounted technical biases by using the LD Score approach.18 We
observed an LD Score intercept of 1.09, which was used to adjust the
association results of the eQTL tested. Lastly, EUGENE was used as
described above to perform the gene-based analysis for all genes selected
for replication.Association analyses contrasting patients with a
single allergic disease
The case-control phenotype analyzed in ourGWAS6 combined information
from asthma, hay fever, and eczema and therefore was expected to improve
power to identify risk variants shared between but not specific to any of the
3 diseases.25 To understand whether gene-based associations discovered
through analysis of that multiple-disease phenotype were indeed likely to
represent risk factors shared across allergic diseases, we performed
case-only association analyses, as described in detail previously.6
First, we tested the association between eQTLs of selected genes with 3
phenotypes that contrasted 3 nonoverlapping groups of adults with a single
allergic disease: asthma-only cases (group 1; n 5 12,268) versus hay
fever–only cases (group 2; n 5 33,305); asthma-only cases (group 1) versus
eczema-only cases (group 3; n 5 6,276); and hay fever–only cases (group 2)
versus eczema-only cases (group 3). For a given eQTL, results from these
analyses indicate whether the risk allele is more (odds ratio [OR] >1) or less
(OR < 1) common in, for example, group 1 when compared with group 2. For
example, if an eQTL contributed similarly to the risks of asthma and hay fever
but not eczema, then one would expect an OR of approximately 1 in the
asthma-only versus hay fever–only comparison but an OR of greater than 1 in
the asthma versus eczema and hay fever versus eczema analyses.
Second, for each gene and phenotype tested, we combined association
results across eQTLs by using EUGENE, as we did in the analysis of the
adjusted GWAS results described above.
This study was approved by the Human Ethics Committee of the QIMR
Berghofer Medical Research Institute.RESULTS
Identification of novel risk loci for allergic disease
through gene-based association analysis
An overview of the analytic approach used is shown in Fig 1. To
identify novel risk loci shared between asthma, hay fever, and
eczema, we first adjusted the association results from Ferreira
et al6 for the 136 genome-wide significant SNPs (ie, with
P < 3 3 1028) identified in that study by using approximate
conditional analysis (Fig 2, A). In the resulting adjusted GWAS,
as expected, there were no SNPs associated with disease risk at
a P value of less than 3 3 1028 and located greater than 1 Mb
from the loci reported in Ferreira et al.6 On the other hand, 4
SNPs located in loci reported in that study (in or near CADM3,
SLC39A8, LRRC43, and KLF5) were genome-wide significant
in the conditional but not original analyses, which is consistent
with the presence of additional secondary association signals at
FIG 1. Outline of the analytic approach used.
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enrichment in significant SNP associations in the adjusted
GWAS (see Fig E1 in this article’s Online Repository at
www.jacionline.org), suggesting that many of these associations
are likely to represent true-positive findings.
To identify loci that were likely to contain true-positive
associations, we applied the EUGENE gene-based approach13
to the adjusted GWAS results. Specifically, we tested the associ-
ation between disease risk and 19,432 genes (or other types of
transcripts, such as long noncoding RNAs [lncRNA]) that were
reported to have 1 or more independent eQTLs in 19 tissues or
cell types relevant to allergic disease (see Table E2), including
whole blood, lung, skin, and individual immune cell types.
We identified 30 significant gene-based associations at a
Bonferroni-corrected P value of 2.53 1026, which were located
in 18 loci (Table I).26 The specific eQTLs included in the gene-
based test for each of these 30 genes are listed in Table E3 in
this article’s Online Repository at www.jacionline.org. For 21
genes, the association P value obtained with the gene-based test
was more significant than the P value obtained with the individual
eQTLs most associated with disease risk (Fig 3), indicating that
multiple eQTLs for the same gene were associated with disease
risk (range, 2-7 associated eQTLs per gene; Table I). For 8 genes,
the difference in significance between the most associatedindividual eQTLs and the gene-based test exceeded 1 order of
magnitude (Fig 3). The most extreme example of this was the
SPNS1 gene on chromosome 16p11.2 (gene-based
P 5 3.5 3 1029 versus the best individual eQTL
P 5 4.8 3 1026), for which 6 of the 15 eQTLs tested (identified
in 5 tissues) were nominally associated with disease risk (see
Table E4 in this article’s Online Repository at www.jacionline.
org).
Replication of significant gene-based associations
in an independent sample
Next, we performed a replication study to determine which of
the 30 significant gene-based associations were likely to represent
true-positive findings. To this end, we first identified 71,807 cases
and 162,091 control subjects genotyped by the UK Biobank
study17 who were unrelated to subjects from our initial GWAS.6
We then used EUGENE to test the association in this independent
sample between case-control status and each of the 30 genes iden-
tified above.
There were 20 significant gene-based associations at a conser-
vative significance threshold that accounts for the 30 genes tested
(P <.05/305 .0016; Table I). These included 19 genes located in
11 loci not implicated in allergic disease in previous GWASs:
OR10J5 (chromosome 1q23.2), RP11-534L20.5 (1q32.1),
FIG 2. Summary of association results between allergic disease status and single SNPs or individual genes.
A, Single-SNP association results published by Ferreira et al.6 B, Single-SNP association results obtained
after adjusting the results of Ferreira et al6 for the effect of the 136 genome-wide significant associations
reported in that study. Variants in 4 loci (in CADM3, SLC39A8, and LRRC43 and between KLF5 and KLF12)
were genome-wide significant (ie, P < 33 1028) in the adjusted but not original GWAS results and therefore
represent secondary single-SNP association signals in loci identified in Ferreira et al.6 C, Gene-based asso-
ciation results obtained for 19,432 genes after applying the EUGENE approach to results from the adjusted
GWAS. Genes with a gene-based association P value of less than 2.5 3 1026 are listed, with font color re-
flecting the evidence for association with those genes in the UK Biobank replication study: green,
P < .0016 (ie, significant after correcting for 30 genes tested); blue, .0016 < P < .05 (ie, nominally significant);
and black, P > .05 (ie, not significant).
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FERREIRA ET AL 695FOSL2 (2p23.2), RBM15B and VPRBP (3p21.2), IPCEF1
(6q25.2), AC004893.11 (7q22.1), PRR5L (11p13), NSMCE1
(16p12.1), SPNS1 and 7 other nearby genes (16p11.2), and
PVALB and NCF4 (22q12.3). Of note, 9 of these genes have a
known function that is directly relevant to the pathophysiology
of allergic disease (Table II).27-48Predicted directional effect of gene expression on
disease risk
Because the gene-based approach used focuses exclusively on
eQTLs, which in turn are associated with expression of specific
genes, wewere able to identify in a single analysis both novel risk
loci and the likely gene or genes underlying each association.
Furthermore, often (but not always), the directional effect of an
eQTL on gene expression can be obtained from published eQTL
studies. Based on this information, for each gene, we determined
whether the allergy-protective allele of eQTLs included in thegene-based test was associated with increased or decreased gene
expression. This is important because drugs that mimic the
directional effect of the allergy-protective allele on gene expres-
sion might be expected to attenuate (rather than exacerbate)
allergic disease symptoms.
When we performed this analysis for the 20 genes with a
significant (P < .0016) association in the replication study, we
found that for 14 genes, the allergy-protective allele was associ-
ated with increased gene expression (see Table E5 in this article’s
Online Repository at www.jacionline.org). This includes, for
example, the lncRNA RP11-534L20.5, for which information
from 6 different tissues (including blood, lung, and skin) indicates
that increased gene expression has a protective effect on disease
risk. On the other hand, for 4 genes (AC004893.11, ATXN2L,
NSMCE1, and RP11-24N18.1), the allergy-protective allele was
associated with decreased gene expression, whereas for 2 genes,
eQTL directional effects were conflicting between studies
(IPCEF1 and SULT1A1).


























with P < .05
EUGENE
P value
1 CASZ1* 1 10696661 rs12045923 4.9E-07 2 1 1.9E-06 2 1 2.0E-02
2 OR10J5 1 159504793 rs2427837 1.0E-05 3 3 2.3E-06 3 3 6.3E-07
3 RP11-534L20.5 1 206677281 rs11117858 8.1E-06 12 5 1.3E-06 11 3 1.1E-03
4 FOSL2 2 28615315 rs7562 8.8E-07 1 1 8.8E-07 1 1 2.6E-04
5 RBM15B 3 51428731 rs73078636 1.4E-07 1 1 1.4E-07 1 1 4.0E-04
VPRBP 3 51433298 rs73078636 1.4E-07 1 1 1.4E-07 1 1 4.0E-04
6 TICAM2 5 114914339 rs17137937 2.9E-06 3 2 1.7E-06 3 1 5.7E-03
7 NUP43 6 150045451 rs6909158 7.5E-06 22 6 2.1E-06 22 1 4.5E-01
8 IPCEF1 6 154475631 rs9397706 4.7E-07 4 3 4.3E-07 4 3 4.1E-07
9 AC004893.11 7 98610788 rs4236540 8.1E-07 1 1 8.1E-07 1 1 4.3E-04
10 ABO* 9 136125788 rs550057 2.8E-07 14 5 1.7E-07 14 6 3.8E-10
11 PTPLA 10 17631958 rs7092926 6.8E-07 4 4 8.2E-07 4 0 2.1E-01
TMEM236 10 17794251 rs7092926 6.8E-07 3 3 1.9E-06 3 0 3.6E-01
12 PRR5L 11 36317838 rs7925585 2.8E-06 6 2 9.7E-07 6 2 1.4E-06
13 NSMCE1 16 27236312 rs4523932 5.2E-06 2 2 6.6E-07 2 2 1.3E-06
14 APOBR 16 28505970 rs151233 3.2E-06 2 2 1.6E-08 2 2 3.8E-05
IL27 16 28510683 rs231970 4.8E-06 2 2 2.6E-08 2 2 1.6E-04
SULT1A1 16 28616903 rs75539558 1.6E-06 8 3 2.0E-07 8 4 1.4E-05
ATXN2L 16 28834356 rs8056890 1.7E-06 1 1 1.7E-06 1 1 1.7E-04
RP11-24N18.1 16 28841933 rs8056890 1.7E-06 1 1 1.7E-06 1 1 1.7E-04
SPNS1 16 28985542 rs2726040 4.8E-06 15 6 3.5E-09 14 5 7.4E-04
RP11-264B17.4 16 28986294 rs8045689 6.3E-06 3 2 1.1E-06 3 2 1.5E-03
LAT 16 28996147 rs8045689 6.3E-06 3 2 1.1E-06 3 3 2.4E-04
15 MYO1C 17 1367392 rs56157500 9.2E-05 4 3 1.5E-06 4 1 5.6E-02
16 ICAM1 19 10381511 rs1799969 1.8E-05 12 7 5.1E-07 12 0 4.1E-01
CTD-2369P2.8 19 10396477 rs1799969 1.8E-05 12 7 5.1E-07 12 0 4.1E-01
ICAM4 19 10397643 rs1799969 1.8E-05 12 7 6.1E-07 11 0 4.9E-01
17 FPR1 19 52248425 rs7254019 1.8E-05 14 7 1.5E-08 14 3 3.2E-03
18 PVALB 22 37196728 rs4821544 3.6E-07 5 2 1.3E-07 5 4 5.9E-05
NCF4 22 37257030 rs4821544 3.6E-07 5 2 4.8E-08 5 3 1.1E-04
The replication P value is shown in boldface if significant after correcting for the 30 genes tested (ie, P < .05/305 .0016) and in italics if .0016 < P < .05 (ie, nominally significant).
*Located in a locus identified in a previous GWAS of allergic disease.26
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single allergic disease
The multiple-disease case-control phenotype analyzed in our
GWAS6 maximizes power to identify risk variants that are shared
between asthma, hay fever, and eczema.25 As such, we expected
the 11 novel risk loci identified above to have comparable effects
on the 3 individual diseases. To address this possibility, we tested
the association between the 20 genes in those 11 loci and 3 phe-
notypes that compared 3 nonoverlapping groups of adults with a
single allergic disease: (1) asthma-only cases (n5 12,268) versus
hay fever–only cases (n5 33,305); (2) asthma-only cases versus
eczema-only cases (n 5 6,276); and (3) hay fever–only cases
versus eczema-only cases. After correcting for the number of tests
performed (P <.05/[20 genes3 3 phenotypes]5 .0008), no single
gene had a significant association in the asthma versus hay fever,
asthma versus eczema, or hay fever versus eczema analyses (see
Table E6 in this article’s Online Repository at www.jacionline.
org). Even at a nominal P value of less than .05, which does not
correct for multiple testing, only 3 genes (in 2 loci) had a signif-
icant association in these analyses:OR10J5, RP11-264B17.4, and
LAT. These results indicate that most, if not all, of the 11 novelrisk loci identified in this study do not have differential effects
on the 3 individual diseases.DISCUSSION
By analyzing results from our previous GWAS6 with a
gene-based test of association, followed by replication of top
findings in an independent sample, we identified 11 loci that
contain previously unrecognized genetic risk variants for allergic
disease. Results from case-only association analyses indicate that
these loci have similar effects on asthma, hay fever, and eczema
risk.
The 11 novel risk loci were not reported in the original GWAS
because they did not contain any single SNP associated with
disease risk at a significance threshold that accounted for the
number of SNPs tested. We were able to identify these loci in the
present study for 2main reasons. First, by testing individual genes
rather than SNPs, themultiple testing burdenwas reduced greatly;
this translated into a less stringent threshold required to declare
genome-wide significance (P5 2.53 1026 instead of 33 1028),
which increases power. Second, most of these loci (7/11) contain
FIG 3. Comparison of results obtained with single-SNP and gene-based
analyses for the 30 genes with a significant gene-based P value (ie,
P < 2.5 3 1026) in the discovery study. For each gene, the x-axis shows
the statistical evidence for association (2log10 P value) obtained with the
eQTL most strongly associated with disease risk. The y-axis shows the ev-
idence for association (2log10 P value) obtained for each gene with the EU-
GENE gene-based approach. Gene names are shown for 8 genes, for which
the latter was at least 1 order of magnitude more significant than the
former. The color of each circle indicates the number of independent eQTLs
for that gene that were individually associated with disease risk at a P value
of less than .05: black (1 associated eQTL), green (2 associated eQTLs), yel-
low (3 associated eQTLs), and red (>_3 associated eQTLs).
TABLE II. Genes with a known function that is relevant to the
pathophysiology of allergic disease
Gene Relevant function References
FOSL2 B cell and epidermal differentiation, TH17
and adipocyte function
27-30
VPRBP T-cell function, B-cell development, viral
replication
31-33
IPCEF1 Binds cytohesin 2, which is involved in
IL-1b signaling and cell adhesion
34-36
PRR5L mTOR interactor that regulates cell death 37
NCF4 Phagocyte oxidative burst, antigen
presentation
38, 39
APOBR Macrophage receptor for apolipoprotein B48 40
IL27 Regulation of TH1 and TH2 responses, Treg
cell function, epithelial cell proliferation
41-44
ATXN2L Cytokine signaling 45
LAT T-cell development and activation 46-48
mTOR, Mammalian target of rapamycin.
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associated with disease risk. Under this scenario, the gene-
based test used improves power over the alternative approach of
testing individual eQTLs separately. Overall, our results support
the use of gene-based eQTL-centric approaches to identify novel
risk loci for human diseases and traits, as reported by others.10,49
Our results point to 19 genes as being the likely candidates
underlying the association between the 11 new loci and allergic
disease risk. However, we stress that functional studies are now
required to confirm that the expression of these genes (1) is
determined by (not simply associatedwith) the eQTLs included in
the respective gene-based test and (2) influences disease
pathophysiology. In other words, for a given locus, we cannot
exclude the possibility that a gene with a significant association is
not causally related to disease pathophysiology. Instead, for
example, it might simply share eQTLs with a nearby causal gene
that was not identified in our analysis. We highlight one possible
example of this.
We observed a genome-wide significant association with a
single gene in the 1q23.2 locus: the olfactory receptor gene
OR10J5 (P5 2.33 1026). This gene is thought to regulate lipid
accumulation50 and therefore could plausibly contribute to the
pathophysiology of allergic disease. However, there were 4 addi-
tional genes within 1 Mb of OR10J5 that had a statistically
(although not genome-wide) significant gene-based association
in our discovery analysis: FCER1A (P 5 1.2 3 1025), DARC(P 5 .0005), IFI16 (P 5 .009), and PYHIN1 (P 5 .03), with the
latter reported previously to contain asthma risk variants in pop-
ulations of African ancestry.51 The association with the first 2
replicated in the independent UK Biobank sample
(P 5 4.8 3 1027 and P 5 .0001, respectively). Therefore it is
possible that FCER1A, DARC, or both represent causal genes un-
derlying the observed association at this locus. Both are biologi-
cally plausible candidate allergy risk genes, encoding,
respectively the a subunit of the high-affinity IgE receptor and
an atypical chemokine receptor.52
Why did our analysis identify OR10J5 and not, for example,
FCER1A? The gene-based test for OR10J5 included 3 eQTLs
(see Table E2), all of which were individually associated
(P < .05) with disease risk; the strongest disease association was
observed for eQTL rs2427838 (single SNP, P 5 1.0 3 1025).
On the other hand, the gene-based test forFCER1A included these
same 3 eQTLs (ie, these eQTLswere shared betweenOR10J5 and
FCER1A) plus an additional 6 independent eQTLs, none of which
were individually associated with disease risk. Because the addi-
tional eQTLs tested for FCER1Awere not associated with disease
risk, the resulting gene-based association was weaker when
compared with OR10J5. An interesting question is why some
but not all eQTLs of FCER1A (and other genes) are associated
with disease risk; for example, it could be that disease associa-
tions are restricted to eQTLs that influence gene expression in a
specific subset of immune cells or to eQTLs that influence multi-
ple relevant genes. Future studies that address this question are
warranted.
With the caveat in mind that significant gene-based associa-
tions pinpoint causal risk loci but not necessarily the right causal
gene or genes, we note that 9 of the 19 genes located in novel risk
loci encode proteins with a known function that is directly
relevant to allergic disease (Table II). For example, FOSL2 is
involved in B-cell and epidermal differentiation.27,28 Further-
more, it has a critical yet complex role in TH17 differentiation
and function29: on the one hand, it represses TH17 signature genes
(eg, IL17A), but on the other hand, it promotes expression of
genes that drive TH17 maintenance and survival (eg, IL6R).
29
When we compared the directional effect of FOSL2 eQTLs be-
tween disease risk and gene expression, we found that the allele
associated with reduced disease risk was associated with
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increased FOSL2 expression results in attenuated allergic inflam-
matory responses. Consistent with this possibility, deletion of a
FOSL2 repressor in mice decreased the capacity of CD41 T cells
to develop into the proinflammatory T follicular helper cell line-
age after immunization with ovalbumin or viral infection or in the
context of low-grade chronic inflammation.53 Based on these ob-
servations, we suggest that therapeutic strategies that increase
FOSL2 expression should be considered for the treatment of
allergic diseases.
Another example of a gene identified in our analysis and
previously implicated in the pathophysiology of allergic disease
was IL27. This was one of 8 genes identified on chromosome
16p11.2, a region that overlaps a large (approximately 0.45 Mb)
and common (49% frequency in Europeans) genomic inversion
previously reported to be associated with the joint occurrence
of asthma and obesity.54 Of the 2 eQTLs included in the gene-
based test for IL27, one (rs7191548) is in high LD (r2 5 0.72)
with an SNP that tags the inversion (rs4788101), suggesting
that the association observed with IL27 in our study is explained
partly by that large structural variant. IL-27 has been shown to
suppress TH2 responses
41,55 and therefore has been suggested
as a potential new therapy for asthma. However, to our
knowledge, no clinical trials have been performed to test this
possibility. Our observation that the allele associated with
reduced disease risk was associated with increased gene
expression in blood for both IL27 eQTLs tested provides further
support for an anti-inflammatory effect of IL-27 in the treatment
of allergic conditions.
Lastly, we identified 4 significant gene-based associations with
noncoding RNAs of unknown function. Of these, the lncRNA
RP11-534L20.5 is of particular interest because it is located in
close proximity (8kb) to IKBKE, a regulator of the nuclear factor
kB pathway that plays a role in immune-related mechanisms.56,57
Using data from release v7 of the GTEx project,58 we found a
highly significant positive correlation in gene expression between
RP11-534L20.5 and IKBKE in the skin (P 5 10211), with a
weaker but consistent effect in blood and lung tissue (data not
shown). Such an association could arise, for example, if
RP11-534L20.5 regulates IKBKE expression or if both transcripts
share a regulatory element. Consistent with the latter hypothesis,
the 59 end of RP11-534L20.5 overlaps a peak of H3K27
acetylation (a mark for active enhancers) in multiple cell lines
and physically interacts with the IKBKE promoter in a B-cell
line.59 Further studies are warranted to investigate the function
of RP11-534L20.5, as well as the other noncoding RNAs
identified in our analysis.
Two additional caveats should be considered when interpreting
results from our study. First, our original GWAS6 included only
subjects of European ancestry, and therefore it is unclear whether
the risk loci identified in our current study extend to subjects of
other ancestries. Second, the association analyses performed to
compare subjects with a single allergic disease were based on a
relatively small sample size, and therefore it is possible that the
lack of significant associations reflects the lower power of these
analyses.
In conclusion, we identified significant and reproducible
gene-based associations with 19 genes located in 11 loci not
previously reported in GWASs of allergic disease. Our genetic
findings suggest that drugs that target these genes might have an
increased probability of success if prioritized for clinicaldevelopment.60 Our results further demonstrate the utility of
applying gene-based tests of association to results from existing
GWASs.
Key messages
d The risk of developing asthma, hay fever, and/or eczema
is associated with genetic variants that influence the
expression of 19 genes located in 11 novel risk loci for
allergic disease, including FOSL2, VPRBP, IPCEF1,
PRR5L, NCF4, APOBR, IL27, ATXN2L, and LAT.
d Gene-based association methods that focus on regulatory
variants can help identify genetic risk factors for human
traits and diseases that were missed by single-variant an-
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